Format

Send to

Choose Destination
Circulation. 2018 Oct 9;138(15):1605-1607. doi: 10.1161/CIRCULATIONAHA.118.036862.

Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.

Author information

1
Division of Cardiac Surgery, St. Michael's Hospital and University of Toronto, Ontario, Canada (S.V.).
2
Division of Endocrinology and Metabolism, St. Michael's Hospital, and University of Toronto, Ontario, Canada (L.A.L.).
3
Department of Anasthesia, St. Michael's Hospital, and University of Toronto, Ontario, Canada (C.D.M.).
4
Institute of Life Science, Swansea University, United Kingdom (S.C.B.).
5
University of North Carolina School of Medicine, Chapel Hill, NC (J.B.).
6
HCA Midwest Health Heart and Vascular Institute, Kansas City, MO (S.M.).
7
Diabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University Bochum, Germany (M.N.).
8
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Ontario, Canada (B.Z.).
9
Novo Nordisk A/S, Søborg, Denmark (H.B.-T., S.R., M.M.M.).
10
Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA (D.L.B.).

KEYWORDS:

diabetes mellitus; liraglutide

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center